Sunshine Biopharma, Inc.
SBFM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | 0.01 | -0.00 |
| FCF Yield | -705.48% | -144.77% | -57.16% | -23.96% |
| EV / EBITDA | 1.29 | 2.36 | 0.43 | -0.62 |
| Quality | ||||
| ROIC | -22.73% | -23.93% | -119.80% | -115.55% |
| Gross Margin | 30.60% | 34.61% | 39.05% | 48.42% |
| Cash Conversion Ratio | 2.44 | 1.95 | 0.20 | 0.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 100.20% | 372.48% | 293.35% | 121.14% |
| Free Cash Flow Growth | -55.30% | -72.21% | -203.61% | -177.78% |
| Safety | ||||
| Net Debt / EBITDA | 1.69 | 4.09 | 0.80 | 0.01 |
| Interest Coverage | -662.41 | -34.85 | -685.10 | -7.42 |
| Efficiency | ||||
| Inventory Turnover | 2.15 | 2.75 | 0.81 | 1.12 |
| Cash Conversion Cycle | 126.97 | 111.63 | 227.72 | 206.71 |